Researchers from Iama Therapeutics Srl and the Italian Institute of Technology have prepared and tested solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of complex regional pain syndromes, Alzheimer’s disease, Down syndrome, glioma, Rett syndrome, temporal lobe epilepsy, traumatic brain injury and obsessive-compulsive disorder.
Muna Therapeutics ApS has synthesized triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of Alzheimer’s disease, inflammatory bowel disease, metabolic syndrome, multiple sclerosis, obesity, Parkinson’s disease, rheumatoid arthritis and stroke, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered new heteroarylphenyl ether derivatives acting as cyclin-dependent kinase CDK8/cyclin C inhibitors. As such, they are reported to be useful for the treatment of graft-vs.-host disease, transplant rejection, multiple sclerosis, rheumatoid arthritis, atopic dermatitis, psoriasis, amyotrophic lateral sclerosis and stroke, among others.
Serine/threonine-protein kinase WNK1 inhibitors have been described in a Dania Therapeutics ApS patent as potentially useful for the treatment of cancer and hypertension.
Pelemed Co. Ltd. has prepared pyrrolotriazine derivatives acting as tyrosine-protein kinase Yes (YES1) inhibitors reported to be useful for the treatment of cancer.
Work at Libra Therapeutics Inc. has led to the identification of new mucolipin-1 (MCOLN1; TRPML1) activators reported to be useful for the treatment of metabolic diseases, infections, hematologic diseases, inflammation, cardiovascular, eye, neurological and renal disorders, among others.
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
RSS